Our Samer Al Hadidi, MD,MS,FACP and Oncology Brothers discussed algorithms for patients with relapsed/refractory #MultipleMyeloma . oncbrothers.com/rr-myeloma-alg… #uamsmyeloma #uamscancer #WPRCI #uamshealth #OncEd #mmsm

Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis

Led by: Heba Altarawneh | هبة الطراونة

✅ ASH & ASCO are doing excellent job in improving women authorship👇

✅>50% of authors reported COI

➡️ Free access: authors.elsevier.com/a/1j5Ij7tJEDVw…

Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis

Led by: Heba Altarawneh | هبة الطراونة

✅ ASH & ASCO are doing excellent job in improving women authorship👇

✅>50% of authors reported COI

➡️ Free access: authors.elsevier.com/a/1j5Ij7tJEDVw…

#HemeSeries : This is the #Algorithm we have used during our discussion w/ Samer Al Hadidi, MD,MS,FACP for R/R #MultipleMyeloma

#HemeTwitter #OncTwitter #MedTwtitter #mmsm #MedEd CancerNetwork® #OncEd OncoAlert

#HemeSeries : w/Samer Al Hadidi, MD,MS,FACP we discuss Rx options for R/R #MultipleMyeloma

Full discussion:
- cancernetwork.com/treatment-algo…
- Oncbrothers.com/rr-myeloma-alg…
- Also on the “Oncology Brothers” podcast

#HemeTwitter #MedTwitter #OncTwitter CancerNetwork® #MMsm

It was pleasure to discuss with Oncology Brothers relapsed/refractory myeloma and how to decide on subsequent therapies #mmsm CancerNetwork® UAMS Myeloma Center UAMS Cancer

Check this out 👇

#HemeSeries : This is the #Algorithm we have used during our discussion w/ Caitlin Costello, MD for Newly Diagnosed #MultipleMyeloma

-Relapsed/Refractory #Myeloma discussion w/ Samer Al Hadidi, MD,MS,FACP to follow.

#HemeTwitter #OncTwitter #MedTwtitter #mmsm #MedEd CancerNetwork® #OncEd OncoAlert

A nice podcast on recent CART approvals in the earlier line settings. Lots of nuanced information .
- differences b/w CARTITUDE and KARRMA
- how to interpret the data
Raj Chakraborty Eddie Cliff Samer Al Hadidi, MD,MS,FACP

So excited to share the panel with my colleagues.

⚠️crucial transition

Fellowship 🔜 attending

Come and ask the key questions ⁉️❓🙋🏻‍♀️ about your first job.

#ASCO2024 H.O.M.E Mentorship Initiative

Montefiore Health System

Come join us #ASCO24 ASCO ASCOTECAG Hem-Onc Fellows Network Trainee Lounge , Saturday, June 1
Preparing for the Transition from Fellowship – Navigating Important Decisions (8-8:45 AM)

I will be speaking along with other colleagues:
Coral Olazagasti, MD
Ilana Schlam
Dr Carolina Ramirez

Samer Al Hadidi, MD,MS,FACP has shown that trials do not f/up patients long-enough to answer important Q.

pubmed.ncbi.nlm.nih.gov/37601879/

I would love 4 vs 4 trials, answering quality of life+MRD questions. Or de-escalation after initial intense therapy.

But I dont think thats what we will see.

Upfront use of Carfilzomib (median age 75) AmericanJournalofHematology #mmsm

➡️ onlinelibrary.wiley.com/doi/10.1002/aj…

🛑 maintenance K vs observation: no difference
🛑 G3 or more infections ~20%
🛑 ~20% of enrolled pts discontinued 2ry to AEs

Safer options: Dara-Rd is the way to go for most pts >75

Check our recent publication: B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
#mmsm

➡️onlinelibrary.wiley.com/doi/full/10.10…
Talquetamab 1st➡️BCMA BsAb or CAR-T
✅Median F/U:9.5 months(range:6–24mo)
✅Median PFS: 5.5 months (range:1–10mo)

Dynamic Prognostic Survival Model Incorporating PROs for TIE Patients With MM with Hsien Seow PhD Amaris Balitsky Tanya Wildes MD Alissa Visram. Thank you Leukemia & Lymphoma Society of Canada for funding Canadian research with ICES Myeloma Canada McMaster Research Hamilton Health Sciences ECRI - ESCARPMENT CANCER RESEARCH INSTITUTE…

In our piece just out in NatureRevClinOncol, Aaron Goodman - “Papa Heme” and I draw attention to overtreatment of multiple myeloma and its precursor states and highlight how de-escalation is an urgent need in clinical practice and in trials.

#mmsm

rdcu.be/dFqsN

Check out my editorial: Clinical Trials of T-Cell Re-Directing Therapy in Plasma Cell Precursor Conditions #mmsm

➡️free access: authors.elsevier.com/a/1ivNN3QE--Z9…

Table 👇 with trials in MGUS&smoldering myeloma

I summarize reasons why such trials are problematic&can harm patients

Samer Al Hadidi, MD,MS,FACP If an IRB truly understood how bad our risk stratification models are, and how much better the natural history of SMM is compared to older historical data, they would never approve such studies, IMO.

Excellent editorial by Samer Al Hadidi, MD,MS,FACP about use of T-cell redirecting therapy in myeloma precursor conditions.

Tox of talquetamab can be horrendous- my patients recall it long after moving on to diff treatment.

I disagree with studying it in MGUS/SMM

tinyurl.com/4uvs444s

Check our recent article: Targeting GPRC5D in multiple myeloma #mmsm UAMS Myeloma Center led by Dr Shatha Elemian from 🇯🇴 (Internal medicine resident interested in hematology-Oncology fellowship) Hem-Onc Fellows Network

Free access for first 50:
➡️ tandfonline.com/doi/full/10.10…

Summary tables 👇

#EBMT24 Bored between sessions and feel like the cacophony around carfilzomib dosing in myeloma #MMsm has become molto FORTE?

Help us standardize our field's practice!

12 questions, <3 min. 🙏 to physicians from 28 countries who've already responded!

redcap.link/carfilzomib